Q1 Earnings Forecast for Annovis Bio Issued By HC Wainwright

Annovis Bio, Inc. (NYSE:ANVS - Free Report) - Investment analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Annovis Bio in a research report issued on Monday, June 9th. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings of ($0.42) per share for the quarter. HC Wainwright has a "Buy" rating and a $12.00 price target on the stock. The consensus estimate for Annovis Bio's current full-year earnings is ($2.19) per share. HC Wainwright also issued estimates for Annovis Bio's Q2 2026 earnings at ($0.39) EPS, Q3 2026 earnings at ($0.43) EPS, Q4 2026 earnings at ($0.42) EPS and FY2026 earnings at ($1.66) EPS.

Several other equities analysts have also commented on ANVS. D. Boral Capital reiterated a "hold" rating on shares of Annovis Bio in a research report on Monday, February 10th. Canaccord Genuity Group lowered their price target on shares of Annovis Bio from $26.00 to $17.00 and set a "buy" rating for the company in a report on Thursday, May 15th. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $30.25.

Annovis Bio Price Performance

Shares of NYSE ANVS traded down $0.17 during midday trading on Tuesday, reaching $2.89. 568,532 shares of the stock traded hands, compared to its average volume of 737,383. The company's 50 day moving average is $1.77 and its 200 day moving average is $3.11. Annovis Bio has a one year low of $1.11 and a one year high of $17.88. The stock has a market capitalization of $56.33 million, a PE ratio of -0.65 and a beta of 1.62.

Annovis Bio (NYSE:ANVS - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.32) EPS for the quarter, beating analysts' consensus estimates of ($0.47) by $0.15.

Institutional Investors Weigh In On Annovis Bio

Several hedge funds and other institutional investors have recently made changes to their positions in ANVS. Two Sigma Investments LP bought a new position in Annovis Bio during the 4th quarter valued at about $55,000. XTX Topco Ltd purchased a new position in shares of Annovis Bio during the fourth quarter valued at approximately $59,000. Atria Wealth Solutions Inc. bought a new position in shares of Annovis Bio during the fourth quarter valued at approximately $65,000. Lokken Investment Group LLC grew its stake in shares of Annovis Bio by 49.0% during the fourth quarter. Lokken Investment Group LLC now owns 18,235 shares of the company's stock valued at $92,000 after buying an additional 6,000 shares during the last quarter. Finally, Greenwich Wealth Management LLC raised its holdings in shares of Annovis Bio by 93.9% in the fourth quarter. Greenwich Wealth Management LLC now owns 31,951 shares of the company's stock worth $161,000 after buying an additional 15,476 shares during the period. Hedge funds and other institutional investors own 15.83% of the company's stock.

Annovis Bio Company Profile

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.